Posted by Michael Wonder on 04 Aug 2021
New CAR T-cell therapy option now available in Australia for patients with aggressive blood cancer
5 August 2021 - Eligible patients can now access Yescarta through Peter MacCallum Cancer Centre, Melbourne and Royal Brisbane and Women’s Hospital, Brisbane, with Sydney sites to follow.
Kite today announced that its Chimeric Antigen Receptor T cell therapy, Yescarta (axicabtagene ciloleucel), is now publicly funded and available to patients in Australia.
Yescarta is now funded for the treatment of adult patients with relapsed or refractory CD-19 positive; diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma who meet the eligibility criteria.
